Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — FY2024 Earnings Presentation
12 slides from Tty Biopharm's earnings presentation, Mar 26, 2025
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2025.03.26
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Operational Results Report 2024 agenda
Operational Results Report 2024 Operational Highlights 2024 Financial Performance 01 2024 Operational Highlights 2025 Outlook 2
Slide 4: Strong Revenue Growth in 2024
6,000 5,062 5,506 5,8945.836 Strong Revenue Growth in 2024 5,000 Consolidated 5 Revenue 4,000 4.4 4.54 Consolidated 3,000 4 營運成果報告 with Continued Expansion in Overseas Markets Operating Profit 2,000 EPS 1,000 1,228 1,372 1,394 3 - 2 Revenue Overview Y2022 Y2023 Y2024 2024 Operational √ Consolidated
Slide 5: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results 營運成果報告 2024 Operational Highlights 2024 Financial Performance 2025 Outlook 4
Slide 6: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation 營運成果報告 • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets 2024 Operational Oncology 2025 2026 2027 Highl
Slide 7: Deploy Globally and Expand Overseas Market
Deploy Globally and Expand Overseas Market Operational Results Report • License-in/ collaboration/ sales 130 drugs in 18 countries globally. • The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets. 2024 • Deepen cooperation with AS
Slide 8: Financial Performance
Operational Results Report 2024 Operational Highlights 2024 Financial Performance 02 2024 Financial Performance 2025 Outlook 7
Slide 9: Financial Performance
Financial Performance Operational Results Report Income Statement （Unit: NT Thousand, 2024 2023 YoY % 2024 Financial Performance except EPS） • YoY consolidated revenue was 58.9 billion, +7% due to 2024 Net Sales 5,893,847 5,505,542 7% the high growth of overseas markets and Intensive Care Operationa
Slide 10: 2024 Steady Revenue Growth
2024 Steady Revenue Growth Operational Results Report 2024 Revenue Breakdown 2024 Revenue Growth 2024 Operational Highlights Product Category % Revenue (NT Mn) 19% 6,200 Oncology 41% 16 6,000 301 2024 3% 5,894 -9 -29 Financial Intensive Care -30 5,800 Performance 140 Healthcare 5,600 5,505 16% CDMO
Slide 11: 2025 Outlook
Operational Results Report 2024 Operational Highlights 2024 Financial Performance 03 2025 Outlook 2025 Outlook 10
Slide 12: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report Strengthen Global Deployment 2024 Operational Highlights 1 Explore potential products and expand international market through authorization, distribution, strategic cooperation and M&A. International Regulations License-in